Endogenous inhibitors of angiogenesis. A historical review

Leukemia Research

Volumn 33, Issue 5, 2009, Pages 638-644

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Antiangiogenesis; Endogenous inhibitors; Tumor growth

Indexed keywords

2 METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTITHROMBIN III; ARRESTEN; CANSTATIN; CHONDROMODULIN; CYTOKINE; ENDOREPELLIN; ENDOSTATIN; FIBRONECTIN; FIBULIN; INTERFERON; PIGMENT EPITHELIUM DERIVED FACTOR; PROLACTIN; PROTHROMBIN KRINGLE 2; TARGETING FIBRONECTIN BINDING INTEGRIN; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TROPONIN I; TUMSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASOSTATIN;

ANGIOGENESIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 61649113720     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.11.019     Document Type: Review

References (97)

1. Nyberg P., Xie L., and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 65 (2005) 3967-3979
2. Sund M., Xie L., and Kalluri R. The contribution of vascular basement membranes and extracellular matrix to mechanics of tumor angiogenesis. APMIS 112 (2004) 450-462
3. Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 6 (2000) 2520-2526
4. Sudhakar A., Nyberg P., Keshamouni V.G., Mannam A.P., Li J., Sugimoto H., et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest 115 (2005) 2801-2810
5. Kamphaus G.D., Colorado P.C., Panka H., Hopfer H., Ramchandran R., Torre A., et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275 (2000) 1209-1215
6. Petitclerc E., Boutard A., Prestayko A., Xu J., Sado Y., Ninomiya Y., et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 275 (2000) 8051-8061
7. Mongiat M., Sweeney S.M., San Antonio J.D., Fu J., and Iozzo R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278 (2003) 4238-4249
8. Bix G., Iozzo R.A., Cardi C., Thakur M.L., Barker C.A., Camphausen K., et al. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 98 (2006) 1634-1646
9. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
10. Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M., et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 274 (1999) 11721-11726
11. Dhanabal M., Ramchandarn R., Volk R., Stillman I.E., Lombardo M., Iurela-Arispe M.L., et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59 (1999) 189-197
12. Dixelius J., Cross M., Matsumoto T., Sasaki T., Timpl R., and Claseson-Welsh L. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 62 (2002) 1944-1947
13. Kim Y.M., Jang J.W., Lee O.H., Yeon J., Choi E.Y., Kim K.W., et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinases. Cancer Res 60 (2000) 5410-5413
14. Kim Y.M., Hwang S., Pyun B.J., Kim T.Y., Lee S.T., Gho Y.S., et al. Endostatin blocks vascular endothelial growth factor signaling via direct interaction with KDR/Flk-1. J Biol Chem 277 (2002) 27872-27879
15. Kisker O., Becker C.M., Pro X., Fannon M., D'Amato R., Flynn E., et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61 (2001) 7669-7674
16. Sund M., Hamano Y., Sugimoto H., Sudhakar A., Soubasakps M., Yerramalla U., et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 102 (2005) 2934-2939
17. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induced acquired drug resistance. Nature 390 (1997) 404-407
18. Folkman J., and Jalluri R. Tumor angiogenesis. In: Kufe D.W., et al. (Ed). Cancer Medicine (2003), BC Decker, Hamilton, Ontario 161-194
19. Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., et al. Endostatin's antiangiogenic signaling network. Mol Cell 13 (2004) 649-663
20. Zorick T.S., Mutsacchi Z., Bandos Y., Zatz M., Moreira-Filho C.A., Olsen B., et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 9 (2001) 811-814
21. Yang Q., Rasmussen S.A., and Friedman J.M. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population based study. Lancet 359 (2002) 1019-1025
22. Pasqualini R., Bourdoulous S., Koivunen E., Woods Jr. V.L., and Ruoslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med 2 (1996) 1197-1203
23. Yi M., and Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis and metastasis. Proc Natl Acad Sci USA 98 (2001) 620-624
24. George E.L., Georges-Labouesse E.N., Patel-King R.S., Rayburn H., and Hynes R.O. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119 (1993) 1079-1091
25. Lee B.H., and Ruoslahti E. Alpha 5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca+/calmodulin-dependent protein kinase IV. J Cell Biochem 95 (2005) 1214-1223
26. Kim S., Harris M., and Varner J.A. Regulation of integrin alpha v beta 3-mediated endothelial cell migration and angiogenesis by integrin alpha 5 beta 1 and protein kinase A. J Biol Chem 275 (2000) 33920-33928
27. Kalluri R. Discovery of type IV collagen non-collageneous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harb Symp Quant Biol 67 (2002) 255-266
28. Albig A.R., and Schiemann W.P. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 23 (2004) 367-379
29. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87 (1990) 6624-6628
30. Taraboletti G., Roberts D., Liotta L.A., and Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 111 (1990) 765-772
31. Iruela-Arispe M.L., Bornstein P., and Sage H. Thrombospondin exterts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 88 (1991) 5026-5030
32. Ferrari D., Outeiro-Bernstein M.A., Nunes S.S., Andrade A.C., Alves T.R., Legrand C., et al. A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan. Matrix Biol 21 (2002) 311-324
33. Lawler J., and Detmar M. Tumor progression: the effects of thrombospondin-1 and-2. Int J Biochem Cell Biol 36 (2004) 1038-1045
34. Bocci G., Francia G., Man S., Lawler J., and Kerbel R.S. Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100 (2003) 12917-12922
35. Noh Y.H., Matsuda K., Hong Y.K., Kunstfeld R., Riccardi L., Koch M., et al. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol 121 (2003) 1536-1543
36. Nicosia R.F., and Tuszynski G.P. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 124 (1994) 183-193
37. Qian X., Wang T.N., Rothman V.L., Nicosia R.F., and Tuszynski G.P. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 235 (1997) 403-412
38. Taraboletti G., Morbidelli L., Donnini S., Parenti A., Granger H.J., Giavazzi R., et al. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J 14 (2000) 1674-1676
39. Chandrasekaean L., He C.Z., Al-Barazi H., Krurzsch H.C., Iruela-Arispe M.L., and Roberts D.D. Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell 11 (2000) 2855-2900
40. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 107 (2001) 929-934
41. Maeshima Y., Colorado P.C., Torre A., Houlthaus K.A., Grunkemeyer J.A., Ericksen M.B., et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275 (2000) 21340-21348
42. Maeshima Y., Colorado P.C., and Kalluri R. Two RGD-independent alpha v beta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275 (2000) 23745-23750
43. Maeshima Y., Manfredi M., Reimer C., Holthaus K.A., Hopfer H., Chandamuri B.R., et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 276 (2001) 15240-15248
44. Maeshima Y., Yerramalla U.L., Dhanabal M., Holthaus K.A., Barbashov S., Kharbanda S., et al. Extracellular matrix-derived peptide binds to alpha(v) beta(3) integrin and inhibits angiogenesis. J Biol Chem 276 (2001) 31959-31968
45. Maeshima Y., Sudhakar A., Lively J.C., Ueki K., Kharbanda S., Khan C.R., et al. Tumstatin, an endostatin cell-specific inhibitor of protein synthesis. Science 295 (2002) 140-143
46. Strander H. Interferon treatment of human neoplasia. Adv Cancer Res 46 (1986) 1-265
47. Brouty-Boye D., and Zetter D. Inhibition of cell motility by interferon. Science 208 (1980) 516-518
48. Sidky Y.A., and Borden E.C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47 (1987) 5155-5161
49. Dvorak H.F., and Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 81 (1989) 497-502
50. Shing Y., Folkman J., Haudenschild C., Lund D., Crum R., and Klagsbrun M. Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem 29 (1985) 275-287
51. Slaton J.W., Perrotte P., Inoue K., Dinney C.P., and Fidler I.J. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5 (1999) 2726-2734
52. Ezekowitz R.A., Mulliken J.B., and Folkman J. Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326 (1992) 1456-1463
53. Kaban L.B., Mulliken J.B., Ezekowitz R.A., Egg D., Smith P.S., and Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 103 (1999) 1145-1149
54. Kaban L.B., Troulis M.J., Egg D., August M., Hornicek F.J., and Dodson T.B. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 60 (2002) 1103-1111
55. Ginns L.C., Roberts D.H., Mark J., Brush I.L., and Marler J.J. Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline. Chest 124 (2003) 2017-2022
56. Cozzolino F., Torcia M., Aldinucci D., Ziche M., Almerigogna F., Bani D., et al. Interelukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci USA 87 (1990) 6487-6491
57. Volpert O.V., Fong T., Koch A.E., Peterson J.D., Waltenbaugh C., Tepper R.I., et al. Inhibition of angiogenesis by interleukin-4. J Exp Med 188 (1998) 1039-1046
58. Morini M., Albini A., Lorusso G., Moelling K., Lu B., Cilli M., et al. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy. Gene Ther 11 (2004) 284-291
59. Yao L., Pike S.E., Setsuda J., Parekh J., Gupta G., Raffeld M., et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96 (2000) 1900-1905
60. Cao R., Farnebo J., Kurimoto M., and Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 13 (1999) 2195-2202
61. Steele F.R., Chader G.J., Johnson L.V., and Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci USA 90 (1993) 1526-1530
62. Dawson D.W., Volpert O.V., Gillis P., Crawfrod S.E., Xu H., Benedict W., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
63. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 8 (2002) 330-334
64. Crawford S.E., Stellmach V., Ranalli M., Huang X., Huang L., Volpert O., et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 114 (2001) 4421-4428
65. Doll J.A., Stellmach V.M., Bouck N.P., Bergh A.R., Lee C., Abramson L.P., et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 9 (2003) 774-780
66. Rastenejad F., Polverini P.J., and Bouck N.P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56 (1989) 345-355
67. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
68. O'Reilly M.S., Homgren L., Cehn C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2 (1996) 689-692
69. Larsson H., Sjoblom T., Dixelius J., Ostman A., Ylinenjarvi K., Bjork I., et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 60 (2000) 6723-6729
70. Lee T.H., Rhim T., and Kim S.S. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem 273 (1998) 28805-28812
71. O'Reilly M.S., Pirie-Shepherd S., Lane W.S., and Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285 (1999) 1926-1928
72. Taylor S., and Folkman J. Protamine is an inhibitor of angiogenesis. Nature 297 (1982) 307-312
73. Maione T.E., Gray G.S., Petro J., Hunt A.J., Donner A.L., Baure S.I., et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247 (1990) 77-79
74. Sharpe R.J., Byers H.R., Scott C.F., Bauer S.I., and Maione T.E. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82 (1990) 848-853
75. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477 (2000) 267-283
76. Moses M.A., Sudhalter J., and Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 248 (1990) 1408-1410
77. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
78. Hiraki Y., Tanaka H., Inoue H., Kondo J., Kamizono A., and Suzuki F. Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes. Biochem Biophys Res Commun 175 (1991) 971-977
79. Hiraki Y., Kono T., Sato M., Shukunami C., and Kondo J. Inhibition of DNA synthesis and tube morphogenesis of cultured vascular endothelial cells by chonromodulin-I. FEBS Lett 415 (1997) 321-324
80. Hayami T., Shukunami C., Mitsui K., Endo N., Tokunaga K., Kondo J., et al. Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEBS Lett 458 (1999) 436-440
81. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppress tumour growth. Nature 368 (1994) 237-239
82. Mabjeesh N.J., Escuin D., Lavallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
83. D'Angelo G., Struman I., Martial J., and Weiner R.I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 92 (1995) 6374-6378
84. Pfeifer A., Kessler T., Silletti S., Cheresh D.A., and Verma I.M. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci USA 97 (2000) 12227-12232
85. Brooks P.C., Silletti S., Von Schalscha T.L., Friedlander M., and Cheresh D.A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92 (1998) 391-400
86. Brooks P.C., Strombland S., Sander L.C., Von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85 (1996) 683-693
87. Kendall R.L., Wang B., and Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226 (1996) 324-328
88. Sawano A., Takahashi T., Yamaguchi S., Aonuma M., and Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Diff 7 (1996) 213-221
89. Kendall R.L., and Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90 (1993) 10705-10709
90. Belgore F.M., Blann A.D., and Lip G.Y. SFlt-1, a potential antagonist for exogenous VEGF. Circulation 102 (2000) E108-E109
91. Yoshimura I., Mizuguchi Y., Miyajima A., Asano T., Tadakuma T., and Hayakawa M. Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J Urol 171 (2004) 2467-2470
92. Moses M.A., Wiederschain D., Wu I., Fernandez C.A., Ghazizadeh V., Lane W.S., et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci USA 96 (1999) 2645-2650
93. Feldman L., Rouleau C., and Troponin I. Inhibits capillary endothelial cell proliferation by interaction with the cell's bFGF receptor. Microvasc Res 63 (2002) 41-49
94. Pike S.E., Yao L., Jones K.D., Cherney B., Appella E., Skaguchi K., et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188 (1998) 2349-2356
95. Pike S.E., Yao L., Setsuda J., Jones K.D., Cherney B., Appella E., et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94 (1999) 2461-2468
96. Yao L., Pike S.E., and Tosato G. Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol 71 (2002) 47-53
97. Xiao F., Wei Y., Yang L., Zhao X., Tian L., Ding Z., et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 9 (2002) 1207-1213